Citrate: How to get started and what, when, and how to monitor?

被引：11
|
作者：
Honore, Patrick M. [1 ]
De Bels, David [1 ]
Preseau, Thierry [2 ]
Redant, Sebastien [1 ]
Spapen, Herbert D. [3 ]
机构：
[1] CHU Brugmann, ICU Dept, Pl Van Gehuchtenpl 4, B-1020 Brussels, Belgium
[2] CHU Brugmann, Emergency Dept, Brussels, Belgium
[3] VUB Univ, Univ Ziekenhuis Brussel, Brussels, Belgium
来源：
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE | 2018年 / 6卷 / 03期
关键词：
regional citrate anticoagulation; diluted citrate; monitoring; metabolic complications; CONTINUOUS VENOVENOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT; REGIONAL CITRATE; ANTICOAGULATION; HEMODIAFILTRATION; HEMODIALYSIS; HEPARIN;
D O I：
10.2478/jtim-2018-0026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In most of the case, regional citrate anticoagulation is using diluted citrate around 1% depending on the types used in clinical practice. Diluted citrate is much more safer when compared to highly concentrated citrate around 4% or even more. In clinical practice, trisodium citrate is used in high concentration (around 30%) as a bactericidal agent with anticoagulant properties for locking deep venous catheters used in hemodialysis (HD; close to 25-30% of citrate). In this review article, buffer and anticoagulant potential of citrate are discussed during renal replacement therapy in critically ill patients with particular focus on the practical approach at the bedside.
引用
收藏
页码：115 / 127
页数：13
相关论文
共 50 条
12345